As of 2024-12-14, the EV/EBITDA ratio of Knight Therapeutics Inc (GUD.TO) is 7.06. EV/EBITDA ratio is calculated by dividing the enterprise value by the TTM EBITDA. GUD.TO's latest enterprise value is 503.60 mil CAD. GUD.TO's TTM EBITDA according to its financial statements is 71.37 mil CAD. Dividing these 2 quantities gives us the above GUD.TO EV/EBITDA ratio.
| Range | Selected | |
| Trailing P/E multiples | 5.5x - 8.3x | 7.1x |
| Forward P/E multiples | 4.7x - 7.4x | 5.6x |
| Fair Price | 4.05 - 6.70 | 5.16 |
| Upside | -21.4% - 30.0% | 0.1% |
| Date | EV/EBITDA |
| 2024-12-10 | 7.31 |
| 2024-12-09 | 7.35 |
| 2024-12-06 | 7.31 |
| 2024-12-05 | 7.32 |
| 2024-12-04 | 7.35 |
| 2024-12-03 | 7.40 |
| 2024-12-02 | 7.32 |
| 2024-11-29 | 7.23 |
| 2024-11-28 | 7.16 |
| 2024-11-27 | 7.23 |
| 2024-11-26 | 7.25 |
| 2024-11-25 | 7.23 |
| 2024-11-22 | 7.25 |
| 2024-11-21 | 7.27 |
| 2024-11-20 | 7.14 |
| 2024-11-19 | 7.06 |
| 2024-11-18 | 7.37 |
| 2024-11-15 | 7.11 |
| 2024-11-14 | 7.16 |
| 2024-11-13 | 7.06 |
| 2024-11-12 | 7.00 |
| 2024-11-11 | 7.08 |
| 2024-11-08 | 7.21 |
| 2024-11-07 | 7.06 |
| 2024-11-06 | 7.89 |
| 2024-11-05 | 7.88 |
| 2024-11-04 | 7.76 |
| 2024-11-01 | 7.76 |
| 2024-10-31 | 7.75 |
| 2024-10-30 | 7.69 |
| 2024-10-29 | 7.75 |
| 2024-10-28 | 7.79 |
| 2024-10-25 | 7.62 |
| 2024-10-24 | 7.69 |
| 2024-10-23 | 7.62 |
| 2024-10-22 | 7.71 |
| 2024-10-21 | 7.71 |
| 2024-10-18 | 7.83 |
| 2024-10-17 | 7.76 |
| 2024-10-16 | 7.75 |
| 2024-10-15 | 7.78 |
| 2024-10-11 | 7.89 |
| 2024-10-10 | 7.92 |
| 2024-10-09 | 8.09 |
| 2024-10-08 | 8.12 |
| 2024-10-07 | 8.23 |
| 2024-10-04 | 7.86 |
| 2024-10-03 | 7.92 |
| 2024-10-02 | 7.92 |
| 2024-10-01 | 8.02 |